Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Some people are microdosing certain weight loss drugs in an attempt to reap some of the drugs' benefits with fewer of their side effects. But doctors specializing in weight loss say that ...

Also in today’s edition: ‘no-show’ international student data and significant progress in Israel-Hamas ceasefire talks ...

Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

Retatrutide, an experimental drug by Eli Lilly, shows promising results in weight loss by targeting three hormones, ...

As the new year sparks a wave of weight loss resolutions and millions turn to weight loss medications, rising costs and the growing popularity of compounded alternatives have raised critical questions ...

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.

Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Compounding pharmacies make their own versions of weight loss drugs at a fraction of the price but there are some drawbacks.

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...